127 related articles for article (PubMed ID: 17578163)
1. [The effect of treatment with fenofibrate on the risk profile of patients with metabolic syndrome and mixed dyslipidemia treated on an outpatient basis].
Rosolová H; Bláha V; Ceska R; Hamouz Z; Pelikánová T; Soska V; Soucek M; Sucharda P
Vnitr Lek; 2007 Apr; 53(4):339-46. PubMed ID: 17578163
[TBL] [Abstract][Full Text] [Related]
2. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
3. [How to treat dyslipidemia in patients with metabolic syndrome].
Soška V
Vnitr Lek; 2015; 61(7-8):721-4. PubMed ID: 26375703
[TBL] [Abstract][Full Text] [Related]
4. The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia.
Ghani RA; Bin Yaakob I; Wahab NA; Zainudin S; Mustafa N; Sukor N; Wan Mohamud WN; Kadir KA; Kamaruddin NA
J Clin Lipidol; 2013; 7(5):446-53. PubMed ID: 24079286
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.
Goldberg AC; Bittner V; Pepine CJ; Kelly MT; Thakker K; Setze CM; Lele A; Sleep DJ
Am J Cardiol; 2011 Mar; 107(6):898-905. PubMed ID: 21247520
[TBL] [Abstract][Full Text] [Related]
6. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.
Keech A; Simes RJ; Barter P; Best J; Scott R; Taskinen MR; Forder P; Pillai A; Davis T; Glasziou P; Drury P; Kesäniemi YA; Sullivan D; Hunt D; Colman P; d'Emden M; Whiting M; Ehnholm C; Laakso M;
Lancet; 2005 Nov; 366(9500):1849-61. PubMed ID: 16310551
[TBL] [Abstract][Full Text] [Related]
7. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
Kei A; Liberopoulos E; Tellis K; Rizzo M; Elisaf M; Tselepis A
Eur J Clin Invest; 2013 Jul; 43(7):698-707. PubMed ID: 23600368
[TBL] [Abstract][Full Text] [Related]
8. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.
Muhlestein JB; May HT; Jensen JR; Horne BD; Lanman RB; Lavasani F; Wolfert RL; Pearson RR; Yannicelli HD; Anderson JL
J Am Coll Cardiol; 2006 Jul; 48(2):396-401. PubMed ID: 16843192
[TBL] [Abstract][Full Text] [Related]
9. Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Chironi G; Simon A; Gariepy J; Balice M; Del-Pino M; Levenson J
Am J Hypertens; 2005 Nov; 18(11):1476-81. PubMed ID: 16280285
[TBL] [Abstract][Full Text] [Related]
10. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.
Costet P; Hoffmann MM; Cariou B; Guyomarc'h Delasalle B; Konrad T; Winkler K
Atherosclerosis; 2010 Sep; 212(1):246-51. PubMed ID: 20619837
[TBL] [Abstract][Full Text] [Related]
11. [Consensus for pharmacologic treatment of atherogenic dyslipidemia with statin-fenofibrate combined therapy].
Panel Europeo de Expertos. Versión Española del Grupo de trabajo sobre Dislipemia Aterogénica
Clin Investig Arterioscler; 2016; 28(2):87-93. PubMed ID: 26811267
[TBL] [Abstract][Full Text] [Related]
12. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Scott R; O'Brien R; Fulcher G; Pardy C; D'Emden M; Tse D; Taskinen MR; Ehnholm C; Keech A;
Diabetes Care; 2009 Mar; 32(3):493-8. PubMed ID: 18984774
[TBL] [Abstract][Full Text] [Related]
13. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
14. Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing.
Farnier M
Vasc Health Risk Manag; 2008; 4(5):991-1000. PubMed ID: 19183747
[TBL] [Abstract][Full Text] [Related]
15. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Jones PH; Cusi K; Davidson MH; Kelly MT; Setze CM; Thakker K; Sleep DJ; Stolzenbach JC
Am J Cardiovasc Drugs; 2010; 10(2):73-84. PubMed ID: 20136164
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus.
Reyes-Soffer G; Rondon-Clavo C; Ginsberg HN
Expert Opin Pharmacother; 2011 Jun; 12(9):1429-38. PubMed ID: 21426238
[TBL] [Abstract][Full Text] [Related]
18. [HDL, or non-HDL: that is the question. Possibilities of pharmacological treatment in residual dyslipidaemia].
Bajnok L
Orv Hetil; 2014 Jan; 155(2):62-8. PubMed ID: 24389322
[TBL] [Abstract][Full Text] [Related]
19. [Effect of anthocyanins from Aronia melanocarpa on blood pressure, concentration of endothelin-1 and lipids in patients with metabolic syndrome].
Broncel M; Koziróg-Kołacińska M; Andryskowski G; Duchnowicz P; Koter-Michalak M; Owczarczyk A; Chojnowska-Jezierska J
Pol Merkur Lekarski; 2007 Aug; 23(134):116-9. PubMed ID: 18044341
[TBL] [Abstract][Full Text] [Related]
20. What is the best choice for combination therapy in the management of dyslipidemia of metabolic syndrome?
Turhan H; Yetkin E
Cardiology; 2006; 105(3):139-40; author reply 141. PubMed ID: 16449809
[No Abstract] [Full Text] [Related]
[Next] [New Search]